CD47-targeted cancer immunogene therapy: Secreted SIRPα-Fc fusion protein eradicates tumors by macrophage and NK cell activation-Reference-Cited by-同舟云学术

CD47-targeted cancer immunogene therapy: Secreted SIRPα-Fc fusion protein eradicates tumors by macrophage and NK cell activation

Published:2021-12 Issue: Volume:23 Page:192-204
ISSN:2372-7705
Container-title:Molecular Therapy - Oncolytics
language:en
Short-container-title:Molecular Therapy - Oncolytics

Author:

Billerhart Magdalena,Schönhofer Monika,Schueffl Hemma,Polzer Wolfram,Pichler Julia,Decker Simon^ORCID,Taschauer Alexander,Maier Julia^ORCID,Anton Martina^ORCID,Eckmann Sebastian,Blaschek Manuel^ORCID,Heffeter Petra^ORCID,Sami Haider^ORCID,Ogris Manfred^ORCID

Funder

FFG

Publisher

Elsevier BV

Subject

Pharmacology (medical),Cancer Research,Oncology,Molecular Medicine

Reference50 articles.

1. Immune surveillance of tumors;Swann;J. Clin. Invest.,2007

2. Transforming growth factor-beta regulation of immune responses;Li;Annu. Rev. Immunol.,2006

3. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles;Ricklefs;Sci. Adv.,2018

4. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target;Barclay;Annu. Rev. Immunol.,2014

5. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers;Sikic;J. Clin. Oncol.,2019

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives;Frontiers in Oncology;2024-07-05

2. A new mRNA structure prediction based approach to identifying improved signal peptides for bone morphogenetic protein 2;BMC Biotechnology;2024-05-23

3. ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion;Cell;2024-04

4. A new mRNA structure prediction based approach to identifying improved signal peptides for bone morphogenetic protein 2;2024-01-25

5. The advances in targeting CD47/SIRPα “do not eat me” axis and their ongoing challenges as an anticancer therapy;Oncotarget;2024-01-06